XTR021 / Sinotau Pharma - LARVOL DELTA

First-in-Human Study of a Novel PSMA-Targeted Radiotherapeutic Agent: Safety, Preliminary Efficacy, and Dosimetry of [177Lu]Lu-PSMA-XT in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (EANM 2025) - No abstract available

Clinical • First-in-human • Metastases • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor